Join Growin Stock Community!

浩宇生醫6872.TW Overview

TW StockBiotech. & Medical
(No presentation for 6872)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

浩宇生醫（6872）Overall Performance

浩宇生醫（6872）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

浩宇生醫（6872） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

浩宇生醫（6872）Key Information

浩宇生醫（6872）Profile

NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan. The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others. It also develops NAVIRFA, a navigation system that uses optical 3D surgical tracking technology to monitor the 3D position of the needle tip during ultrasonic interventional procedures. The company was founded in 2015 and is based in Taipei, Taiwan.

浩宇生醫（6872）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
20.90%
Net Margin
-663.77%
Revenue Growth (YoY)
12.19%
Profit Growth (YoY)
142.82%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
20.90%
Net Margin
-663.77%
Revenue Growth (YoY)
12.19%
Profit Growth (YoY)
142.82%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6872

浩宇生醫

19.60D

0.51%

(0.01)

  • When is 6872's latest earnings report released?

    The most recent financial report for 浩宇生醫 (6872) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6872's short-term business performance and financial health. For the latest updates on 6872's earnings releases, visit this page regularly.

  • What is the operating profit of 6872?

    According to the latest financial report, 浩宇生醫 (6872) reported an Operating Profit of -38.79M with an Operating Margin of -1,041.21% this period, representing a decline of 24.44% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6872's revenue growth?

    In the latest financial report, 浩宇生醫 (6872) announced revenue of 3.73M, with a Year-Over-Year growth rate of -70.34%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6872 have?

    At the end of the period, 浩宇生醫 (6872) held Total Cash and Cash Equivalents of 176.68M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6872 go with three margins increasing?

    In the latest report, 浩宇生醫 (6872) did not achieve the “three margins increasing” benchmark, with a gross margin of 20.32%%, operating margin of -1,041.21%%, and net margin of -965.61%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6872's profit trajectory and future growth potential.

  • Is 6872's EPS continuing to grow?

    According to the past four quarterly reports, 浩宇生醫 (6872)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6872?

    浩宇生醫 (6872)'s Free Cash Flow (FCF) for the period is -1.62M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 136.3% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.